Sanofi: Pulmonary Disease, Chronic Obstructive trials
The registry lists 15 Pulmonary Disease, Chronic Obstructive studies with Sanofi as lead sponsor. 7 are open to participants now and 6 have results posted.
Phase 1 1Phase 2 2Phase 3 8Phase 4 1No phase 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Evaluate the Long-term Safety and Efficacy of Lunsekimig in Adult Participants With Chronic Obstructive Pulmonary Disease (COPD)Enrolling by invitationNCT07793409Phase 3
- The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) RegistryRecruitingNCT07612878
- Long-term Real-world Study of Dupilumab in COPD : Patient Characteristics, Safety and Patient-reported OutcomesRecruitingNCT07380711
- Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic PhenotypeRecruitingNCT07190222Phase 3
- Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic PhenotypeRecruitingNCT07190209Phase 3
- A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.RecruitingNCT07053423Phase 4
- Study to Evaluate Long-term Effectiveness and Safety, Patient Characteristics and Subjective Patient-reported Outcomes of Dupilumab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Under Real-world ConditionsRecruitingNCT07052396
- Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPDCompletedNCT05326412Phase 2Results posted
- Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT04751487Phase 3Results posted
- Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT04701983Phase 3Results posted
- Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 InflammationCompletedNCT04456673Phase 3Results posted
- Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 InflammationCompletedNCT03930732Phase 3Results posted
- Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT03546907Phase 2Results posted
- A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPDCompletedNCT06208306Phase 3
- Pharmacokinetic Study to Compare Itepekimab Exposure When Administered With an Autoinjector Versus Prefilled SyringeCompletedNCT06114238Phase 1